Vitro Biopharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Vitro BioPharma, Inc. filed its Form 10-Q for the quarter ended April 30, 2026, detailing a net loss of $1.55 million and highlighting substantial doubt about its ability to continue as a going concern.
Vitro BioPharma reported a reduced net loss in Q1 2026 but continues to face substantial doubt about its ability to continue as a going concern due to significant working capital deficit and reliance on future capital raises.
Vitro BioPharma reported a significant increase in its quarterly net loss and a worsening working capital deficit, raising substantial doubt about its ability to continue as a going concern.
Vitro BioPharma, Inc. reported a significant reduction in net loss for the three and six months ended April 30, 2025, while acknowledging substantial doubt about its ability to continue as a going concern and actively pursuing new capital.
Vitro Biopharma enters into a security agreement with holders of senior secured convertible notes, granting a lien on company assets to secure obligations under the purchase agreement and notes.